PURPOSE: To evaluate combinations of clinical signs, using a modified World Health Organization (WHO) grading scheme, to predict a very low prevalence of infection at the community level after at least three rounds of mass drug administration (MDA). METHODS: Seventy-one villages had three to seven rounds of MDA. A random sample of 7828 children ages 5 years and younger was evaluated for trachoma, and determination of Chlamydia trachomatis infection was made. Proportions of children positive for infection were evaluated against all possible combinations of follicular trachoma (TF) and inflammatory trachoma (TI). High-risk signs (HRS) for infection were defined as those indicating the infection prevalence was >20%. The sensitivity and specificity of prevalence of HRS in identifying communities with infection was examined. RESULTS: The median community infection prevalence was 3.8% interquartile range (IQR) (1.8%, 7.7%); the median trachoma prevalence was 9.4%, IQR (6.6%, 15%). Severe TI, combination of TF and TI (WHO criteria), or severe TF with signs of inflammation were predictive of infection in the community, but the absence of these HRS was not an indicator of low infection rates. CONCLUSIONS: The use of HRS to determine the infection status of a community was not useful in predicting whether MDA could be stopped.
PURPOSE: To evaluate combinations of clinical signs, using a modified World Health Organization (WHO) grading scheme, to predict a very low prevalence of infection at the community level after at least three rounds of mass drug administration (MDA). METHODS: Seventy-one villages had three to seven rounds of MDA. A random sample of 7828 children ages 5 years and younger was evaluated for trachoma, and determination of Chlamydia trachomatis infection was made. Proportions of children positive for infection were evaluated against all possible combinations of follicular trachoma (TF) and inflammatory trachoma (TI). High-risk signs (HRS) for infection were defined as those indicating the infection prevalence was >20%. The sensitivity and specificity of prevalence of HRS in identifying communities with infection was examined. RESULTS: The median community infection prevalence was 3.8% interquartile range (IQR) (1.8%, 7.7%); the median trachoma prevalence was 9.4%, IQR (6.6%, 15%). Severe TI, combination of TF and TI (WHO criteria), or severe TF with signs of inflammation were predictive of infection in the community, but the absence of these HRS was not an indicator of low infection rates. CONCLUSIONS: The use of HRS to determine the infection status of a community was not useful in predicting whether MDA could be stopped.
Authors: Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West Journal: Ophthalmic Epidemiol Date: 2011-02 Impact factor: 1.648
Authors: Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Jenafir I House; Nisha R Acharya; Travis C Porco; Bruce D Gaynor; Thomas M Lietman Journal: Arch Ophthalmol Date: 2011-04
Authors: Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Travis C Porco; Elizabeth Yi; Jenafir I House; Zhaoxia Zhou; Kathryn J Ray; Nisha R Acharya; John P Whitcher; Bruce D Gaynor; Thomas M Lietman Journal: Am J Trop Med Hyg Date: 2010-03 Impact factor: 2.345
Authors: Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey Journal: N Engl J Med Date: 2004-11-04 Impact factor: 91.245
Authors: H R Taylor; S L Johnson; R A Prendergast; J Schachter; C R Dawson; A M Silverstein Journal: Invest Ophthalmol Vis Sci Date: 1982-10 Impact factor: 4.799
Authors: Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2005-01 Impact factor: 4.799
Authors: Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West Journal: PLoS Negl Trop Dis Date: 2011-03-15
Authors: Anthony W Solomon; Emma Harding-Esch; Neal D E Alexander; Aura Aguirre; Martin J Holland; Robin L Bailey; Allen Foster; David C W Mabey; Patrick A Massae; Paul Courtright; John F Shao Journal: N Engl J Med Date: 2008-04-24 Impact factor: 91.245
Authors: Jithin Yohannan; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Robin Bailey; Thomas A Lietman; Thomas Quinn; Sheila K West Journal: JAMA Ophthalmol Date: 2013-04 Impact factor: 7.389
Authors: Diana L Martin; Rhiannon Bid; Frank Sandi; E Brook Goodhew; Patrick A Massae; Augustin Lasway; Heiko Philippin; William Makupa; Sandra Molina; Martin J Holland; David C W Mabey; Chris Drakeley; Patrick J Lammie; Anthony W Solomon Journal: PLoS Negl Trop Dis Date: 2015-02-25
Authors: Sheila K West; Robin Bailey; Beatriz Munoz; Tansy Edwards; Harran Mkocha; Charlotte Gaydos; Thomas Lietman; Travis Porco; David Mabey; Thomas C Quinn Journal: PLoS Negl Trop Dis Date: 2013-08-29
Authors: E Brook Goodhew; Jeffrey W Priest; Delynn M Moss; Guangming Zhong; Beatriz Munoz; Harran Mkocha; Diana L Martin; Sheila K West; Charlotte Gaydos; Patrick J Lammie Journal: PLoS Negl Trop Dis Date: 2012-11-01
Authors: Alexander Jenson; Laura Dize; Harran Mkocha; Beatriz Munoz; Jennifer Lee; Charlotte Gaydos; Thomas Quinn; Sheila K West Journal: PLoS Negl Trop Dis Date: 2013-07-04